# The Mutation Profile and Prognosis in AML With IDH1/2 Mutation

> **NCT07004816** · — · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 1015 (actual)

## Conditions studied

- AML

## Interventions

- **OTHER:** Uncover mutation profiles

## Key facts

- **NCT ID:** NCT07004816
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-21
- **Primary completion:** 2020-03-24
- **Final completion:** 2020-03-24
- **Target enrollment:** 1015 (ACTUAL)
- **Why stopped:** Adapted the plan
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07004816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07004816, "The Mutation Profile and Prognosis in AML With IDH1/2 Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07004816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*